摘要
目的:研究利托那韦对舒芬太尼在家免体内药动学的影响。方法:将24只家免随机分为两组,每组12只,实验组ig利托那韦10mg/kg,5min后iv舒芬太尼2μg/kg;对照组ig同等容量生理盐水后iv舒芬太尼2 gg/kg。分别于ig前和ig后0、0.25、0.5、1、2、3、4、6、8、10、12、14、24 h自免耳中央动脉取血0.3 ml,采用液相色谱.串联质谱法(LC-MS/MS)测定血浆中舒芬太尼的浓度,DAS2.0软件计算药动学参数。结果:两组家免体内舒芬太尼药动学过程均符合二室模型;对照组与实验组家免体内舒芬太尼的药动学参数t_(1/2)分别为(22.0±6.59)、(26.4±1.41)h,MRT_(0-24h)分别为(8.6±2.08)、(12.1±3.70)h,AUC_(0-∞)分别为(16.1±5.17)、(38.1±12.95)mg·h/L;两组间MRT_(0-24h)、AUC_(0-∞)差异均有统计学意义(P<0.05)。结论:利托那韦可提升舒芬太尼在家免体内的分布,延长舒芬太尼滞留时间。
OBJECTIVE：To study the effects of ritonavir on the pharmacokinetics of sufentanil in rabbits.METHODS：24 rabbits were randomly divided into 2 groups,with 12 rabbits in each group.Trial group was given ritonavir 10 mg/kg by gavage and then injected sufentanil 2 μg/kg intravenously after 5 min.Control group was given equal volume of normal saline by gavage and then injected sufentanil 2 μg/kg intravenously.Arterial blood samples 0.3 ml were taken before gavage and 0,0.25,0.5,1,2,3,4,6,8,10,12,14,24 h after intravenous administration.The plasma concentrations of sufentanil were determined by LC-MS/MS,and DAS 2.0 software was adopted to calculate pharmacokinetic parameters.RESULTS：The pharmacokinetic change of sufentanil conformed to two-compartment model in 2 groups.The pharmacokinetic parameters of sufentanil in control group vs.trial group were that t（1/2） were（22.0 ±6.59） and（26.4 ±1.41） h;MRT（0-24h）Were（8.6 ±2.08） and（12.1 ±3.70） h;AUC（0-∞） were（16.1 ±5.17） and（38.1 ± 12.95） mg·h/L,respectively.There was statistical significance in MRT（0-24h） and AUC（0-∞） between 2 groups（P〈0.05）.CONCLUSIONS：Ritonavir can elevate distribution of sufentanil in rabbits,and prolong retention time of sufentanil.
出处
《中国药房》
CAS
北大核心
2016年第22期3048-3050,共3页
China Pharmacy
基金
上海市卫生局科研课题(No.20124040)
